FMP
ERYTECH Pharma S.A.
ERYP
NASDAQ
Inactive Equity
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
0.78 USD
0.01 (1.28%)
About
ceo
Mr. Gil Beyen M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.erytech.com
exchange
NASDAQ
Description
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
CIK
0001624422
ISIN
US29604W1080
CUSIP
29604W108
Address
60 Avenue Rockefeller
Phone
33 4 78 74 44 38
Country
FR
Employee
49
IPO Date
Jul 5, 2016
Summary
CIK
0001624422
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
29604W108
ISIN
US29604W1080
Country
FR
Price
0.78
Beta
2.13
Volume Avg.
148.59k
Market Cap
47.38M
Shares
-
52-Week
0.3-1.472
DCF
2.91
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-78
P/B
-
Website
https://www.erytech.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ERYP News
It looks like there's no news available.
